HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for NeuroPace in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.15) for the quarter, up from their previous estimate of ($0.16). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.67) EPS.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. The company had revenue of $22.83 million for the quarter, compared to the consensus estimate of $22.61 million. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%.

Several other research firms have also issued reports on NPCE. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a report on Wednesday, June 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a research note on Monday. Finally, Mizuho initiated coverage on shares of NeuroPace in a report on Thursday, July 23rd. They set an “outperform” rating and a $22.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.29.

NeuroPace Trading Down 4.2%

NASDAQ NPCE opened at $14.02 on Friday. NeuroPace has a 12 month low of $8.41 and a 12 month high of $19.60. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The stock’s fifty day moving average price is $15.37 and its 200-day moving average price is $15.33. The stock has a market cap of $481.17 million, a P/E ratio of -24.60 and a beta of 1.92.

Hedge Funds Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in NeuroPace during the second quarter valued at $39,369,000. First Light Asset Management LLC grew its stake in shares of NeuroPace by 82.3% during the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after purchasing an additional 1,110,484 shares during the period. Deutsche Bank AG bought a new stake in shares of NeuroPace during the 2nd quarter valued at about $14,919,000. Kotler Kevin purchased a new stake in shares of NeuroPace during the 4th quarter valued at about $9,750,000. Finally, Walleye Capital LLC lifted its stake in shares of NeuroPace by 344.6% in the 4th quarter. Walleye Capital LLC now owns 228,847 shares of the company’s stock worth $3,533,000 after purchasing an additional 177,375 shares during the period. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.